ranibizumab (Lucentis)

Ranibizumab (rhuFab V2; Lucentis, Genentech, South San Francisco, CA) is a humanized monoclonal antibody fragment designed to bind all forms of VEGF, thereby blocking vessel permeability and angiogenesis in neovascular age-related macular degeneration

Also Known As:

Networked: 1435 relevant articles (242 outcomes, 375 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Souied, Eric H: 29 articles (11/2015 - 02/2008)
2.	Bressler, Neil M: 27 articles (12/2015 - 11/2007)
3.	Kaiser, Peter K: 26 articles (01/2016 - 10/2006)
4.	Brown, David M: 24 articles (12/2015 - 10/2006)
5.	Querques, Giuseppe: 24 articles (11/2015 - 02/2008)
6.	Campochiaro, Peter A: 22 articles (07/2015 - 12/2006)
7.	Schmidt-Erfurth, Ursula: 21 articles (01/2016 - 12/2007)
8.	Bandello, Francesco: 19 articles (09/2015 - 11/2010)
9.	Heier, Jeffrey S: 19 articles (07/2014 - 04/2006)
10.	Rubio, Roman G: 18 articles (11/2014 - 09/2009)

Related Diseases

1.	Macular Degeneration (Age-Related Maculopathy) 07/01/2012 - "In the ranibizumab group, the mean logarithm of the minimum angle of resolution best-corrected visual acuity (Snellen equivalent) with typical age-related macular degeneration (22 eyes) and polypoidal choroidal vasculopathy (18 eyes) statistically significantly (P < 0.0001, P = 0.015, respectively) improved from 0.17 (20/29) and 0.14 (20/28) at baseline to 0.07 (20/24) and 0.07 (20/24) at Month 12, respectively (mean numbers of treatments, 4.6 and 4.9). " 01/01/2012 - "Ranibizumab is an effective treatment for CNV secondary to non-age-related macular degeneration causes, with most patients gaining an improvement in the first 2 months following injection." 12/01/2011 - "Continued ranibizumab treatment appears to be beneficial for patients with neovascular age-related macular degeneration who experience a ≥ 3-line BCVA loss during the first year of treatment." 07/01/2014 - "and (2) Is a higher dose of ranibizumab (2.0 mg/0.05 mL) more effective in treating PCV than the current dose (0.5 mg/0.05 mL) approved for treatment of age-related macular degeneration? " 05/01/2013 - "Intravitreal ranibizumab for the treatment of exudative age-related macular degeneration is effective for stabilizing vision in patients with PED, but it may be better tolerated in patients with serous PED. "
2.	Macular Edema 01/01/2015 - "Ranibizumab IVI in addition to IH proved to be highly effective in increasing visual acuity and reducing macular edema secondary to CRVO. " 12/01/2014 - "Significant reduction of diabetic macular edema following intravitreal ranibizumab injection in the fellow eye." 05/01/2015 - "Intravitreal ranibizumab may be effective in the treatment of long-standing macular edema associated with foveal macroaneurysms. " 05/01/2013 - "In diabetic macular edema, ranibizumab has shown greater efficacy with fewer side-effects than steroid implants. " 12/01/2012 - "Intravitreal ranibizumab appeared to be an effective treatment of macular edema related to Irvine-Gass syndrome. "
3.	Choroidal Neovascularization 05/01/2012 - "We report the first case of choroidal neovascularization associated with Strüpell-Lorrain syndrome treated successfully with intravitreal ranibizumab injection." 10/01/2010 - "The role of ranibizumab in choroidal neovascularization in association with punctate inner choroidopathy has been shown to be beneficial in this small group in whom improvement or stabilization of vision was observed in 9 of 10 eyes. " 09/01/2012 - "Intravitreal ranibizumab and IVB are effective in the treatment of subfoveal myopic choroidal neovascularization. " 05/01/2012 - "Intravitreal ranibizumab may be effective to induce morphological and functional improvement in cases of choroidal neovascularization secondary to adult-onset vitelliform foveomacular dystrophy. " 01/01/2012 - "Intravitreal ranibizumab seems to be an effective and safe option for the treatment of subfoveal choroidal neovascularization in patients with butterfly-shaped PD."
4.	Retinal Vein Occlusion 05/01/2013 - "Early ranibizumab responders had excellent visual outcomes regardless of ranibizumab dose; mean improvement in BCVA letter score at 6 and 12 months was 15.0 to 16.5 (central retinal vein occlusion [CRVO]) and 17.4 to 19.1 (branch retinal vein occlusion [BRVO]). " 05/01/2013 - "In retinal vein occlusion, both ranibizumab and Ozurdex have been shown to be effective, although their relative efficacy has not been determined in head-to-head clinical trials. " 10/01/2011 - "[Influence of serous macular detachment on the efficacy of ranibizumab treatment in retinal vein occlusions]." 01/01/2014 - "Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study." 05/01/2013 - "Both ranibizumab and steroid implants can be considered in retinal vein occlusion, but trials are awaited to determine their relative efficacy."
5.	Diabetic Retinopathy (Retinopathy, Diabetic) 09/01/2007 - "The efficacy of ranibizumab has been studied in 3 large clinical trials having the same primary efficacy end point, the proportion of patients losing <15 letters from baseline at 12 months (Early Treatment of Diabetic Retinopathy Study chart). " 01/01/2012 - "The mean visual acuity in the ranibizumab alone group improved from 52.9 Early Treatment of Diabetic Retinopathy letters initially to 62.8 letters at twelve months. " 12/01/2015 - "All patients participating in the OLE were eligible to receive 0.5 mg ranibizumab according to predefined re-treatment criteria: Treatment was administered when DME was identified by the investigator on optical coherence tomography or when best-corrected visual acuity (BCVA) worsened by ≥5 Early Treatment Diabetic Retinopathy Study letters versus month 36. " 12/01/2015 - "Patients with Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) from 20/32 to 20/500 (Snellen equivalent) were randomized to receive intravitreal 0.5 mg ranibizumab monthly or according to a TREX protocol. " 01/01/2015 - "Lucentis offers treatment alternative for diabetic retinopathy, trial finds."

Related Drugs and Biologics

1.	bevacizumab
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
3.	ranibizumab (Lucentis)
4.	aflibercept
5.	Retinaldehyde (Retinal)
6.	1-phenyl-3,3-dimethyltriazene (PDT)
7.	verteporfin (Visudyne)
8.	pegaptanib
9.	salicylhydroxamic acid (SHAM)
10.	Dexamethasone (Maxidex)

Related Therapies and Procedures

1.	Intravitreal Injections
2.	Injections
3.	Photochemotherapy (Photodynamic Therapy)
4.	Lasers (Laser)
5.	Intraocular Injections